These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 27641633)

  • 1. Biophysical Activity of Impaired Lung Surfactant upon Exposure to Polymer Nanoparticles.
    Beck-Broichsitter M
    Langmuir; 2016 Oct; 32(40):10422-10429. PubMed ID: 27641633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compatibility of PEGylated Polymer Nanoparticles with the Biophysical Function of Lung Surfactant.
    Beck-Broichsitter M
    Langmuir; 2018 Jan; 34(1):540-545. PubMed ID: 29220196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biophysical inhibition of synthetic vs. naturally-derived pulmonary surfactant preparations by polymeric nanoparticles.
    Beck-Broichsitter M; Ruppert C; Schmehl T; Günther A; Seeger W
    Biochim Biophys Acta; 2014 Jan; 1838(1 Pt B):474-81. PubMed ID: 24184425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poloxamer-Decorated Polymer Nanoparticles for Lung Surfactant Compatibility.
    Beck-Broichsitter M; Bohr A; Ruge CA
    Mol Pharm; 2017 Oct; 14(10):3464-3472. PubMed ID: 28813610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biophysical inhibition of pulmonary surfactant function by polymeric nanoparticles: role of surfactant protein B and C.
    Beck-Broichsitter M; Ruppert C; Schmehl T; Günther A; Seeger W
    Acta Biomater; 2014 Nov; 10(11):4678-4684. PubMed ID: 25087869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of cholesterol and budesonide on biophysical properties of clinical surfactant.
    Zhang H; Wang YE; Neal CR; Zuo YY
    Pediatr Res; 2012 Apr; 71(4 Pt 1):316-23. PubMed ID: 22391630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biophysical activity of animal-derived exogenous surfactants mixed with rifampicin.
    Kolomaznik M; Calkovska A; Herting E; Stichtenoth G
    Adv Exp Med Biol; 2015; 839():31-9. PubMed ID: 25252905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of agglomeration and specific lung lining lipid/protein interaction on short-term inhalation toxicity.
    Wohlleben W; Driessen MD; Raesch S; Schaefer UF; Schulze C; Vacano Bv; Vennemann A; Wiemann M; Ruge CA; Platsch H; Mues S; Ossig R; Tomm JM; Schnekenburger J; Kuhlbusch TA; Luch A; Lehr CM; Haase A
    Nanotoxicology; 2016 Sep; 10(7):970-80. PubMed ID: 26984182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations.
    Seeger W; Grube C; Günther A; Schmidt R
    Eur Respir J; 1993 Jul; 6(7):971-7. PubMed ID: 8370446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structures of pulmonary surfactant films adsorbed to an air-liquid interface in vitro.
    Bachofen H; Gerber U; Gehr P; Amrein M; Schürch S
    Biochim Biophys Acta; 2005 Dec; 1720(1-2):59-72. PubMed ID: 16405864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biophysical models in investigations of exogenous surfactant activities on the surface tension and their theurapeutic effectiveness].
    Todorov R; Iordanova A; Georgiev GA; Petkova Kh; Stoimenova E; Georgieva R; Khristova E; Vasiliev Kh; Lalchev Z
    Akush Ginekol (Sofiia); 2007; 46 Suppl 1():29-36. PubMed ID: 18175392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biophysical investigation of pulmonary surfactant surface properties upon contact with polymeric nanoparticles in vitro.
    Beck-Broichsitter M; Ruppert C; Schmehl T; Guenther A; Betz T; Bakowsky U; Seeger W; Kissel T; Gessler T
    Nanomedicine; 2011 Jun; 7(3):341-50. PubMed ID: 21059405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse biophysical effects of hydroxyapatite nanoparticles on natural pulmonary surfactant.
    Fan Q; Wang YE; Zhao X; Loo JS; Zuo YY
    ACS Nano; 2011 Aug; 5(8):6410-6. PubMed ID: 21761867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioinspired polymer nanoparticles omit biophysical interactions with natural lung surfactant.
    Beck-Broichsitter M; Bohr A
    Nanotoxicology; 2019 Sep; 13(7):964-976. PubMed ID: 31109226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biophysical and chemical stability of surfactant/budesonide and the pulmonary distribution following intra-tracheal administration.
    Chen CM; Chang CH; Chao CH; Wang MH; Yeh TF
    Drug Deliv; 2019 Dec; 26(1):604-611. PubMed ID: 31204848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivation of pulmonary surfactant due to serum-inhibited adsorption and reversal by hydrophilic polymers: experimental.
    Taeusch HW; Bernardino de la Serna J; Perez-Gil J; Alonso C; Zasadzinski JA
    Biophys J; 2005 Sep; 89(3):1769-79. PubMed ID: 15923228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Properties of modified natural surfactant after exposure to fibrinogen in vitro and in an animal model of respiratory distress syndrome.
    Calkovska A; Linderholm B; Haegerstrand-Björkman M; Curstedt T
    Pediatr Res; 2012 Sep; 72(3):262-9. PubMed ID: 22691953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of pulmonary surfactant adsorption by serum and the mechanisms of reversal by hydrophilic polymers: theory.
    Zasadzinski JA; Alig TF; Alonso C; Bernardino de la Serna J; Perez-Gil J; Taeusch HW
    Biophys J; 2005 Sep; 89(3):1621-9. PubMed ID: 16006630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyaluronan decreases surfactant inactivation in vitro.
    Lu KW; Goerke J; Clements JA; Taeusch HW
    Pediatr Res; 2005 Feb; 57(2):237-41. PubMed ID: 15585679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A biophysical mechanism by which plasma proteins inhibit lung surfactant activity.
    Holm BA; Enhorning G; Notter RH
    Chem Phys Lipids; 1988 Nov; 49(1-2):49-55. PubMed ID: 3233711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.